



HealthTech Investment Days

12 & 13 May 2025 - Lisbon, Portugal

HOSTED BY



JOSÉ DE MELLO



European
Innovation
Council



Funded by
the European Union

This project has received funding from the
European Union, under Grant Agreement N° 101114582.

SUMMARY

Page

The EIC Scaling Club: Purpose, Structure, and Impact	4
EIC Scaling Club Roadshow	
Healthtech Investment Days In Lisbon	6
Agenda	8
Selected Start-Ups	10
Attendees	21

THE EIC SCALING CLUB: PURPOSE, STRUCTURE, AND IMPACT

We are on a mission to boost and showcase Europe's deep tech excellence.

The EIC Scaling Club is a curated and EIC-funded community where 120 European deep tech scale-ups with the potential to build world-class businesses and solve major global challenges come together with investors, corporate innovators, and other industry stakeholders to spur growth.

The top 120 European deep tech companies are carefully selected from a pool of high-growth deep tech scale-ups that have benefitted from EIC financial schemes, other European and national innovation programmes, and beyond to support their growth.

The EIC Scaling Club is more than a community; it's a dynamic ecosystem that unites:




120 deep tech scale-ups;
100+ investors;
100+ corporate partners;
100+ mentors;
50+ government agencies;
50+ media & clusters.

All driven by ambitious goals:

- Grow the companies' value through tailored coaching sessions, access to relevant business partners, investors and others;
- Addressing societal needs – Tackling significant challenges in Digital, Mobility & Transportation, Health, Energy & Climate, Materials and more.

10 Market Groups:



Digital Sector

-  Next-Gen Computing
-  Digital Security & Trust
-  New Space

Climate Sector

-  Smart Mobility
-  Renewable Energies
-  Batteries & Energy Storage
-  Clean Fuels & Hydrogen
-  Agri & Food Tech

Health Sector

-  Cardiovascular Therapies
-  New Biotech Platforms

EIC Scaling Club companies have raised over €3 billion in funding to date, driving innovation, job creation, and sustainable growth across Europe.



The HealthTech Investment Days, part of the EIC Scaling Club Roadshow and funded by the European Innovation Council (EIC), is a two-day event co-organised by José de Mello, CUF, and EurA.

Taking place on 12–13 May 2025 in Lisbon, the event is designed to connect Europe's most promising health deep tech scaleups with leading investors, corporates, and innovation stakeholders.

Day one, hosted by José de Mello, is dedicated to investment opportunities. The programme includes exclusive insights at José de Mello Capital, curated scaleup presentations, and targeted one-on-one investor meetings.

Day two, hosted by CUF, focuses on corporate collaboration and innovation. Highlights include expert-led panel discussions, pitching sessions, an award ceremony recognising standout solutions, and guided tours of CUF's facilities.

This event offers selected companies from the EIC Scaling Club and the EIC Awardees portfolio with a unique opportunity to showcase their technologies, forge strategic partnerships, and accelerate their growth within the European healthtech ecosystem.



AGENDA DAY ONE



Roadshow: HealthTech Investment Days by EIC Scaling Club,
hosted by José de Mello - 12 May 2025

12:00 – 12:30	Registration & Welcome Bites
12:30 – 12:35	Welcome Address
12:35 – 12:40	EIC Scaling Club Overview
12:40 – 13:00	Inside José de Mello Capital: CellmAbs Insights & Learnings
13:00 – 13:20	From Lisbon to Europe: Building Europe's Innovation Future Together
13:20 – 15:00	Pitching Session I – Health companies
15:00 – 15:30	Coffee Break
15:30 – 17:10	Pitching Session II – Health companies
Next Stop: José de Mello Headquarters	
17:10 – 17:20	Group Photo & Coffee Break
17:20 – 19:00	Business Meetings
19:00 – 21:00	Networking Dinner & Cocktail

AGENDA DAY TWO



Roadshow: HealthTech Investment Days by EIC Scaling Club,
hosted by CUF - 13 May 2025

09:00 – 09:30	Registration & Welcome Coffee
09:30 – 09:35	Opening Remarks
09:35 – 09:45	EIC & EIC Scaling Club Overview
09:45 – 10:05	Panel: <i>Co-Creating Tomorrow's Healthcare</i>
10:05 – 11:45	Pitching Session I – Health companies
11:45 – 11:55	Coffee Break
11:55 – 13:30	Pitching Session II – Health companies
13:30 – 13:45	Group Photo & Awards Ceremony
13:45 – 14:15	Lunch Break
14:15 – 16:30	Business Meetings & CUF Hospital Innovation Tour

For full agenda details, please check the online event page.

Western European Summer Time (WEST)

SELECTED START-UPS

EIC AWARDEES

ACORAI

Acorai is setting a new benchmark in heart failure management with a non-invasive, AI-powered intracardiac pressure monitoring device—previously only measurable via implants. Designed for outpatient and at-home use, this breakthrough enables earlier detection, reduces rehospitalisations, and delivers scalable impact for millions of chronic care patients.

Sweden <https://acorai.com>

ACORAI

Filip Peters
CEO
filip.peters@acorai.com

EIC SCALING CLUB COMPANY

ANACONDA BIOMED

Anaconda Biomed is redefining stroke therapy with a next-generation mechanical thrombectomy system. Its advanced design improves navigation and clot extraction efficiency, with the potential to become the new gold standard in ischaemic stroke intervention—backed by strong clinical momentum and global relevance.

Spain www.anaconda.bio

ANACONDA
BIOMED

Ofir Arad
Managing Director
o.arad@anaconda.bio

Trent Reutiman
CEO
t.reutiman@anaconda.bio

AORTYX SL



Aortyx is transforming treatment for aortic disease with bioresorbable endovascular patches that promote natural tissue regeneration. This minimally invasive, scalable approach lowers surgical risk and offers a breakthrough alternative for high-mortality vascular conditions.

Jordi Martorell
CEO
jordi.martorell@aortyx.com

Spain www.aortyx.com

CARDIAWAVE



Cardiawave is transforming the treatment of aortic stenosis with Valvosoft®, a non-invasive ultrasound therapy that softens calcified heart valves without surgery, anaesthesia, or radiation. Targeting patients unsuitable for valve replacement, this breakthrough offers a safer, repeatable solution that improves mobility and symptoms with minimal risk. Backed by strong clinical data and CE mark trials underway, Cardiawave is positioned to reshape cardiovascular care globally.

Carine Schorochoff
Strategic Advisor
carine.schorochoff@gmail.com

France www.cardiawave.com

CELLPLY



Cellply enables deep functional profiling of immune cells at single-cell resolution—vital for the development of effective cancer immunotherapies. Its high-throughput platform helps pharma and biotech partners optimise the selection, validation, and monitoring of next-generation cell therapies.

Italy www.cellply.com

Massimo Bocchi
Co-founder and Chief Strategy Officer
massimo.bocchi@cellply.com

CHECK POINT CARE



CheckPoint Care merges AI-powered analytics, wearables, and telemedicine to deliver real-time monitoring and predictive diagnostics for chronic conditions. Its integrated platform drives down healthcare costs while improving patient outcomes through continuous, data-led care.

Bulgaria www.checkpointcardio.com

Kaja Vidic
Chief Business Development Officer
kaja.vidic@checkpointcardio.com

Boris Dimitrov
CEO
b.dimitrov@checkpointcardio.com



CONTEXTFLOW

Contextflow enhances radiology with AI-driven decision support tools that analyse chest CT scans for faster, more accurate diagnosis of pulmonary and cardiovascular diseases. Seamlessly integrated into clinical workflows, it boosts speed, standardisation, and diagnostic confidence.

Julie Sufana
CMO
julie@contextflow.com

Austria www.contextflow.com

Tiago Santos
Customer Success Manager



ELYPTA

Elypta is pioneering a first-in-class metabolic-based liquid biopsy for multi-cancer detection. Using simple urine or blood samples and machine learning, it enables early-stage, non-invasive cancer diagnosis—positioning itself as a scalable solution for pan-cancer screening.

Karl Bergman
CEO
karl.bergman@elypta.com

Sweden www.elypta.com

GENOMTEC S.A.

Genomtec provides laboratory-grade molecular diagnostics in a palm-sized device. Its flagship product, Genomtec ID, delivers ultra-rapid and precise genetic testing at the point of care—empowering fast, decentralised diagnostics in emergency, military, and rural environments with limited lab access.

Poland www.genomtec.com



Michal Wachowski
CFO
m.wachowski@genomtec.com

GLYCANOSTICS

Glycanostics is leading a new wave in cancer diagnostics by identifying glycan biomarkers in blood. With high sensitivity and specificity, its tests offer affordable, early detection for cancers such as prostate and breast—before symptoms arise—dramatically improving patient prognosis.

Slovakia www.glycanostics.com



Eva Kovacova
CEO
eva.kovacova@glycanostics.com

Jan Tkac
CSO
jan.tkac@glycanostics.com

MIMARK DIAGNOSTICS



Mimark Diagnostics is tackling underdiagnosis in women's health with biomarker-based diagnostic tools. Its innovations support earlier and more accurate detection of reproductive disorders and gynaecological cancers, setting new standards for personalised women's healthcare.

Marina Rigau
CEO & co-founder
marina.rigau@mimark.es

Spain www.mimark.es

NEUROKAIRE



NeuroKaire is bringing precision to psychiatry by combining AI, genetic profiling, and patient-derived neurons to recommend personalised treatments for mental health conditions. The platform reduces the current "trial-and-error" approach in prescribing, directly addressing a \$250B global mental health burden.

Talia Cohen Solal
CEO
talia@neurokaire.com

Israel www.neurokaire.com

NOVUS DIAGNOSTICS

Novus is transforming sepsis response with a 15-minute bedside test for bloodstream infections—offering a game-changing innovation in critical care. By enabling earlier, targeted intervention, the technology improves survival rates and reduces ICU costs in one of healthcare's most urgent and deadly emergencies.



Keith O'Neill
CEO
keith@novus-dx.com

Ireland www.novus-dx.com

RDS

RDS powers next-generation remote care through its MultiSense® platform—enabling continuous, real-time monitoring for patients with chronic illnesses. This plug-and-play ecosystem allows healthcare providers to reduce readmissions, better manage risk, and scale proactive care delivery.



Guillaume Calmon
Head of Business Development and Marketing
guillaume.calmon@rdsdiag.com

France www.rdsdiag.com



RIBBON BIO

Ribbon Biolabs is redefining synthetic biology with ultra-fast, automated DNA synthesis at scale. By facilitating rapid prototyping of complex genetic constructs, it unlocks major efficiencies in drug development, gene therapy, and vaccine engineering.

Austria www.ribbonbio.com

Dr David A. Maier
CTO
david.maier@ribbonbiolabs.com

RS RESEARCH



RS Research is revolutionising precision oncology through its polymer-drug conjugate platform, which targets tumours while sparing healthy tissue. Clinically validated and preparing for Series B growth, it represents a safer and more effective alternative to conventional chemotherapy.

Turkey <https://rsresearch.net/>

Rana Sanyal
Co-Founder & CSO
rs@rsresearch.net

Sena Nomak
Co-Founder & COO
sn@rsresearch.net

SEQUENTIA BIOTECH

Sequentia Biotech translates multiomics complexity into clinical clarity. Its AI-powered bioinformatics platforms accelerate drug discovery, precision diagnostics, and personalised treatment strategies—supporting global biopharma, research institutions, and healthcare providers.

Spain <https://www.sequentiabiotech.com/>



Tiago Machado
Sales Director
tmachado@sequentiabiotech.com

VAXDYN

Vaxdyn develops next-generation vaccines targeting multidrug-resistant bacterial infections—a critical and rising global health threat. With clinical trials in progress and broad applicability across low- and middle-income regions, its platform offers high-impact potential for public health and biodefence.

Spain www.vaxdyn.com



Juan Jose Infante Viñolo
CEO
juanjo.infante@vaxdyn.com



WOOPTIX

Wooptix leverages cutting-edge wavefront imaging—originally developed in astronomy—for ultra-precise metrology. While currently used in semiconductor inspection, its high-resolution imaging technology holds promising potential in next-generation biomedical diagnostics.

Roberto
Programme Management Officer
roberto@wooptix.com

Spain www.wooptix.com

ATTENDEES

CORPORATES

AdvanceCare

www.advancecare.com

Silvia Moreira
Director of Provider's Network

Tiago Guerra
Product Manager

AstraZeneca

<https://www.astrazeneca.pt/>

Célia Veríssimo
Diagnostics & Innovation Lead



www.boldinternationalgroup.com

Dusan Obradovic
CEO

CORPORATES

Multicare

www.multicare.pt

Duarte Mónica
Business Development Lead

Sofia Mexia
Head of Business Development



www.multus.bio

Cai Linton
CEO and Co-founder

PHILIPS

<https://www.philips.com/a-w/about/innovation/philips-ventures.html>

Benno Tieke
Director Portfolio Management

Chiesi
Farmaceutici Spa

www.chiesi.com

Vera Codazzi
Innovation Network Manager

FIDELIDADE
SEGUROS DESDE 1898

www.fidelidade.pt

Inês Ramalho
Innovation Specialist

Filipe
Head of Innovation

Marta González
Venture Capital

GE HealthCare
Portugal

www.gehealthcare.com

João Pires
Executive Account Manager

Rui Costa
General Manager Portugal

Roche
Farmacêutica
Química

<https://www.corporate.roche.pt/>

Helena Fareleiro Serra
Healthcare System Partner

Vodafone Portugal

<https://www.vodafone.pt/>

João Ribas
Innovation

Filipa
Marketing Manager



<https://insignals-neurotech.com/>

Sara Reis
CEO

Johnson & Johnson
MedTech

<https://www.jnjmedtech.com/>

Luis Graça
Commercial Excellence Lead

Medtronic

<https://medtronic.sharepoint.com/sites/InsideMDT>

João Branco
Enterprise Account Manager

INVESTORS



www.amadeuscapital.com

Pierre Socha
Partner



www.armilar.com

Inês Santos
Investor

Pedro Castel-Branco
Investor



www.biovancecapital.com

Ricardo Henriques
Managing Partner



www.bynd.vc

Francisco Pinto
Partner



<https://www.cr-ventures.com/>

Nuno Arantes-Oliveira
Partner



<https://dealflow.eu/>

André Moraes Sarmento
Investment Associate

Beatriz Pedrosa
Senior Investment Analyst



www.faber.vc

Alexandre Barbosa
Managing Partner

Sofia Santos
Partner

Gilde Healthcare

<https://gildehealthcare.com/>

Janke Dittmer
General Partner

imec.xpand

www.imecxpand.com

Jonathan Fajardo
Principal

INVESTORS



www.karista.vc

Amine Benmoussa
Partner

Tom Beauvironnet
Investor



www.kiboventures.com

Sonia Fernandez
Partner



www.lifex.vc

Rika Christanto
Partner

Panakès Partners

<https://www.panakes.it/>

Giacomo Piccinini
Investment Manager



<https://www.pathena.com/>

António Murta
Managing Partner and CEO



<https://www.shilling.vc/>

Ricardo Jacinto
Partner



<https://www.speedinvest.com/>

Laurens Asamoah
Capital Formation Analyst



www.ventura-biomed.com

Andreas Jenne
CEO



<https://www.vesaliusbiocapital-4.com/>

David Cristina
Principal

AGENCIES, MENTORS AND OTHERS



www.complear.com

Miguel Amador
CIO

Dr. S. Piperaki
International
Consulting

Stavroula Ina Piperaki
CEO



<https://edgemed.vc/>

Anya Eldan
Partner

EuPA

<https://eupa.bg/index.htm>

Vasil Karaivanov
CEO

EVEURA

Advisory Business Model Design

Ritalba Lamendola
Director



www.impulse4women.org

Taryn Andersen
CEO & coFounder

AGENCIES, MENTORS AND OTHERS

Sequana Medical

pcchauvineau@gmail.com

Pierre Chauvineau
Chairman of the Board

Evolution Europe

www.evolutioneurope.eu

Sofia Fernandes
Head of Business and Investment



<https://mendspace.com>

Pedro Oliveira
Co-founder



<https://www.perceptionparadox.com>

Zivile Einikyte
Creator, Podcaster & Coach

Portugal Ventures

www.portugalventures.pt

Pedro Breyner
Executive Board Member



www.40foundation.org

Vesselin Drobenov
CEO

Independent
Biomedical

Ana Catarina Gomes
Expert



www.interlid.biz

Raúl Izquierdo
CEO and EIC Coach

Projexel

www.projexel.eu

Roland Zonai
CEO

unicorn Factory
Lisboa

<https://unicornfactorylisboa.com/>

Gil Azevedo
Executive Director

Isabel Holguera
International Manager

REPRESENTATIVES FROM JOSÉ DE MELLO



Ana Lopes

Deputy Director Innovation and Sustainability

Bárbara Santos

Deputy Director Business Development

Cláudia Bernardo

Corporate Communications Manager

João de Mello

Member of the Executive Committee

João Mil-Homens

Director Innovation and Sustainability

Luis Brito de Goes

Member of the Executive Committee

Nuno Cochito de Sousa

Director Strategic Planning and Management Control

Pedro Rocha e Melo

Member of the Executive Committee

Rui Diniz

Member of the Executive Committee

Salvador Mello

Chief Executive Officer (CEO)

Vasco de Mello

Chairman of the Board of Directors

Vasco Luis de Mello

General Manager

Francisco Gorjão

Tejo Cluster Administrator

Francisco Lamy

Production Manager at CUF Tejo Hospital

Joana Garcias Tiago

CUF Simulation Center Manager

João Estevão

Commercial Director at CUF

João Leal

Data&Analytics Director at CUF

Marta Barreiros

Clinical Studies Manager at CUF

Marta Cruz Martins

Digital Transformation Director at CUF

Micaela Monteiro

Digital Transformation Clinical Director at CUF

Miguel Viana Baptista

CUF Tejo Hospital Neurology Department's
Clinical Director

Patricia Crespo Loureiro

Digital Transformation Project Manager at CUF

Paula Borralho

CUF Oncology Clinical Director at CUF

Paula Brito Silva

Executive Board Member

Pedro Botelho Neves

Supply Chain & Logistics Manager at CUF

Pedro Garcia

CUF Simulation Center Clinical Director

Pedro Heleno Ribeiro

Head of Procurement at CUF

Pedro Matos

Cardiologist at CUF Tejo Hospital

Ricardo Bastos

Logistics and Procurement Director at CUF

Ricardo Gonçalves Viegas

Innovation Manager at CUF

Rita Costa

CUF Oncology Director at CUF

Rita Rocha Pinto

Innovation Consultant at CUF

Susana Rafael

Digital transformation project manager at CUF

REPRESENTATIVES FROM CUF



Alexandre Amaral e Silva

Neurologist at CUF Tejo Hospital

Ana Raquel Soares

Head Nurse for Clinical Safety at CUF Tejo Hospital

André Alves Viegas

Digital Transformation Project Manager at CUF

António José Fiarresga

CUF Tejo Hospital Cardiology Department's
Clinical Director

Catarina Gato Cardadeiro

Innovation Manager at CUF

Célia Presilha

Commercial Manager at CUF

Cláudia Ferreira da Silva

Head of Innovation and Operational BI

Cláudia Pieck

Operational Communication Manager at CUF

Cláudia Simões

CUF Academic Center Director at CUF

Filipa Moreira

Head of CUF Simulation Center

Filipa Soeiro

CUF Tejo Hospital Director



Follow us!

www.eicscalingclub.eu

